[Skip to Content]
[Skip to Content Landing]
June 11, 1982

Adverse Effect of Hydralazine in Patients With Primary Pulmonary Hypertension

JAMA. 1982;247(22):3112-3114. doi:10.1001/jama.1982.03320470058033

Hydralazine hydrochloride has been recommended as a treatment for primary pulmonary hypertension. Two patients who were so treated experienced further elevation of the pulmonary artery pressure and clinical deterioration. The mechanism of this adverse effect was a decrease of systemic vascular resistance attended by an increase in cardiac output without a fall in the pulmonary vascular resistance. Hemodynamic monitoring is advised in patients undergoing vasodilator therapy for primary pulmonary hypertension.

(JAMA 1982;247:3112-3114)